title: Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review.
abstract: The evidence supporting therapy with imatinib for bleomycin-induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopenia and gastrointestinal bleeding.
authors.affiliation: Department of Pharmacy Frankston Hospital Peninsula Health Frankston Vic. Australia.
authors.forename: Iouri
authors.initials: I
authors.lastname: Banakh
authors.affiliation: Department of Pharmacy Frankston Hospital Peninsula Health Frankston Vic. Australia.
authors.forename: Alice
authors.initials: A
authors.lastname: Lam
authors.affiliation: Department of Intensive Care Medicine Frankston Hospital Frankston Vic.3199 Australia; School of Public Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton Vic. 3800 Australia.
authors.forename: Ravindranath
authors.initials: R
authors.lastname: Tiruvoipati
authors.affiliation: Department of Intensive Care Medicine Frankston Hospital Frankston Vic.3199 Australia; School of Public Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton Vic. 3800 Australia.
authors.forename: Ian
authors.initials: I
authors.lastname: Carney
authors.affiliation: Department of Intensive Care Medicine Frankston Hospital Frankston Vic.3199 Australia; School of Public Health Faculty of Medicine, Nursing and Health Sciences Monash University Clayton Vic. 3800 Australia.
authors.forename: John
authors.initials: J
authors.lastname: Botha
keywords: Bleomycin; imatinib mesylate; intensive care; pulmonary toxicity; respiratory failure; treatment outcome